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www.jacctctabstracts2013.com MONDAY, OCTOBER 28, 2013, 8:00 AM–6:35 PMhemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the ﬂow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MFM* preserves
the collateral branches allowing the possibility to cover any artery without compro-
mising the ﬂow (renal, digestive arteries, supra aortic vessels.)
Results: 40 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8, mesenteric:1,
carotid: 1, Subclavian : 1) were treated with the MFM* (male:31, mean age 62+/-8 y)
(52 stents Ø 5 to 14 mm; length 40 to 120 mm) were implanted to treat these aneu-
rysms, by femoral approach (39 cases), brachial approach (1 case), Technical success
in all patients. No complications. All An. thrombosed with diameter reduction in some
pts. The thrombosis could take several weeks depending on the importance of
collateral branches. 6 month to 36 month follow up will be presented and we will
discuss the time needed to achieve exclusion of the An. All the side branches remained
patent.
Conclusions: A new concept of stent, the MFM* (without any covering) is developed
to treat An. It opens a new approach to treat peripheral An. avoiding most of the
complications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
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Background: Central sleep apnea (CSA), usually presenting as Hunter-Cheyne-
Stokes Breathing, occurs in approximately 35% of patients with heart failure. Current
treatment options for CSA have been limited and focus on mask based therapies and
therefore are highly dependent on tolerability and adherence. A novel therapy utilizing
phrenic nerve stimulation was developed using the remede System, a transvenous,
fully implantable system that is intended to restore a normal breathing pattern
throughout the night. This is the ﬁrst presentation of the study cohort with reduced
ejection fraction (EF) to evaluate of the remede System through 3 and 6 months.
Methods: Subjects received a remede System consisting of a respistimTM trans-
venous stimulation lead (in either the left pericardiophrenic or right brachiocephalic
vein) and a remede pulse generator which was placed in the pectoral area and secured
in a normal fashion. Thirty-ﬁve subjects with predominantly central sleep apnea were
enrolled. Subjects had an ejection fraction < 40% Subjects (age 659 years) and were
able to be evaluated at 3 and 6 months of therapy. 62% percent of subjects had
a concomitant cardiac device and 86% of subjects had chronic heart failure symptoms.
Standard PSG criteria were used for classiﬁcation of respiratory events and arousals.
Results: Both 3 and 6 month data demonstrate signiﬁcant improvements in apnea-
hypopnea index (AHI), central apnea index, oxygen desaturation index of 4%, arousal
index, REM sleep and sleep efﬁciency. In addition, there were signiﬁcant improve-
ments in quality of life at 6 months seen both in MLWHF (p¼0.0012) and NYHA
Classiﬁcation (p<0.0001).Changes in Respiratory and Symptoms with 6 months of remede System
Therapy
Parameter
Baseline
Mean +/-
Std Dev
3 Months
Mean +/-
Std Dev
6 Months
Mean +/- Std
Dev
Paired T-test
(Baseline to 6
Months
Apnea Hypopnea Index
(n/hr)
5115 2513 2413 <0.0001
Central Apnea Index
(n/hr)
3015 59 47 <0.0001
Oxygen Desaturation
Index 4% (n/hr)
4719 2413 2413 <0.0001
Arousal Index (n/hour) 3917 2611 2713 0.0002
Sleep Efﬁciency (%) 6818 7616 8013 0.0002
REM sleep (%) 106 168 186 <0.0001
MLWHFQ 3323 NA 2421 0.0012
Epworth Sleepiness
Scale
7.43.5 NA 4.72.9 <0.0001
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SConclusions: Treatment of CSA with the remede System signiﬁcantly improves
both respiratory and sleep parameters as well as symptoms of heart failure, in patients
with reduced EF. These favorable changes in pathophysiological consequences of
sleep apnea may lead to improvements in outcomes in patients with heart failure.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 Years oTCT-135
Antegrade Transapical Branched Aortic Arch Endograft – a Feasibility Study in
Pigs
Sabine Wipper1, Christina Lohrenz1, Oliver Ahlbrecht1, Mohamad Akkra1,
Sebastian W. Carpenter1, Nikolaos Tsilimparis1, Eike S. Debus1, Christian Detter1,
Axel Larena-Avellaneda1, Tilo Kölbel1
1University Heart Center Hamburg, Hamburg, Germany
Background: To describe the technique and proof the concept of a complete trans-
apical deployment of a single sidebranch arch endograft in a porcine model.
Methods: Eight domestic pigs were operated with antegrade transapical delivery of
a single-sidebranch arch endograft including a mating stentgraft to the innominate
artery. Technical feasibility, operating time, radiation parameters and hemody-
namic changes were studied according to standardized protocol during baseline
(T0), after establishing of the transapical access and through-and-through wire
(T1) and after stent-graft deployment (T2). Myocardial and cerebral perfusion
were assessed by ﬂuorescent-microspheres (FM) and transit-time-ﬂow measure-
ment (TTFM).
Results: Transapical access, introduction and deployment of the endograft, side-
branch catheterization and deployment of the mating stent-graft were feasible in 6 of
the 8 animals with unimpeded perfusion of the innominate artery. One animal was lost
during transapical access, one during sire-branch catheterization. The mean operating
and ﬂuoroscopy times were 15747min and 15.93.2min. During introduction and
deployment of the stent-graft transient aortic valve insufﬁciency occurred in all
animals. Hemodynamic stability recovered within ten minutes after retrieval of the
delivery system in all animals. The innominate artery was patent with unchanged
TTFM-ﬂow measurements throughout the procedure. FM evaluation revealed stable
myocardial and cerebral perfusion.
Conclusions: Antegrade transapical access to the aortic arch for implantation of
a single sidebranch arch endograft is feasible in a porcine model with reversible
impact on hemodynamic measures during deployment. Transapical access allows for
deployment of a complex endograft through a single large bore access-site in a porcine
model. It might be a future treatment option for selective patients.
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Background: Diastolic dysfunction develops in most cardiac conditions, and leads to
elevation of left ventricular ﬁlling pressures and heart failure. We report the initial
experience with a novel device intended to lower left atrial pressure by creating
a small permanent atrial septal shunt. The objective of the study was to evaluate safety
and potential beneﬁts of the Intra Atrial Shunt Device (IASD) System in patients
with symptomatic heart failure with preserved or mildly reduced ejection fraction,
despite appropriate medical management.
Methods: The ﬁrst 6 patients in a prospective multicenter feasibility study were
enrolled under an approved protocol. Key inclusion criteria were: EF > 45%; PCWP
at rest  15 or exercise  25mm Hg; or  1 hospitalization for heart failure within
prior 12 months; or persistent NYHA Class III/IV for at least 3 months.
Results: Mean age, EF, and NYHA Class were 75 Y, 57 %, and III, respectively.
Most patients had multiple comorbidities. The IASD Device was successfully
implanted in each patient using standard interventional techniques and guidance. One
SAE (complete heart block) occurred within 30 days, and resolved (pacemaker). The
SAE was not related to the procedure or device. At 30 days, PCWP was reduced, and
at 30 days clinical symptoms had improved in 5 of 6 patients. Additional follow-up
data will be presented.f Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013 B43
Parameter Baseline Follow-up (d)
m PCWP (mmHg) 18.8 14.3 (30)
(n¼5)
m RAP (mmHg) 11.5 12 (30)
n¼4
RVSP (mmHg) 49.5 52.5 (30)
n¼4
6 MWD (m) 318.5 343.3 (90)
n¼4
NT-Pro-BNP (pmol/L) 294.4 237 (90)
n¼4
MLWHF score 41.8 32.3 (90)
n¼4
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SConclusions: This initial data demonstrates that the shunt device can be safely
implanted and early clinical improvement can be obtained in patients with heart failure
and preserved or mildly reduced ejection fraction. Longer term follow-up is warranted.Antiplatelets and Antithrombins
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No beneﬁt of Clopidogrel Pretreatment in stable patients undergoing elective PCI
Anne Bellemain-Appaix1, Stephen A. O'Connor2, Johanne Silvain3, Michel Cucherat4,
Jean-philippe collet5, Francois Bernasconi6, Gilles Montalescot7
1CH La Fontonne Antibes, Antibes, France, 2Pitié Salpétrière Hospital, Paris,
France, 3Pitie Salpetriere, Paris, France, 4Chu Lyon, Lyon, MS, 5Pitié Sapetriere,
Paris, France, 6CH La Fontonne Antibes, Antibes, MS, 7N/A, Paris, France
Background: Although Clopidogrel pretreatment is recommended (class I-C) for stable
CAD patients scheduled for elective PCI, the beneﬁt of this strategy compared to an
administration at the time of PCI has not been shown on hard clinical outcome. We per-
formed a systematic review and meta-analysis of all RCTs to evaluate the impact of clo-
pidogrel pretreatment on mortality and major bleeding after elective PCI for stable CAD,
as compared with no pretreatment. An additional metaanalysis was done on registries.
Methods: We included studies on elective PCI from MEDLINE, EMBASE, CCTR
databases that reported clinical data on mortality and major bleeding. A random-effect
model was applied. Pretreatment was deﬁned as the administration of clopidogrel
before PCI. The primary efﬁcacy and safety endpoints were all-cause mortality and
major bleeding, respectively. Secondary endpoints included MACE, MI, Stroke,
UVR, Stent Thrombosis (ST), minor and any bleeding.
Results: Of the 392 titles identiﬁed, 6 (3 RCTs and 3 observational) met the inclusion
criteria, published between Aug-2004 and Dec-2012. Of 13628 patients, 1636 were
from RCTs. 55% underwent PCI. Results from the analysis of RCTs are shown in
Figure I. ST, stroke and UVR were not different between groups. In the analysis of
observational data, there was no difference between groups for all cause death, MI and
ST, nor in bleeding. Only MACE and UVR were decreased.B44 JACC Vol 62/18/Suppl B j October 27–NovemConclusions: Clopidogrel pretreatment is not associated with a reduction of mortality,
MACE or ischemic endpoints in stable CAD scheduled for elective PCI, but with an
excess of minor and any bleeding.
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Background: Clopidogrel pretreatment is recommended for the treatment of
NSTEACS patients (class I-B), at a time when the ﬁnal revascularization strategy is
not known. A previous meta-analysis focused on randomized trials suggested a tiny
beneﬁt in patients undergoing PCI. We performed a new meta-analysis of not only
RCTs but also registries to assess the impact of clopidogrel pretreatment in NSTEACS
patients. We evaluated the global effect independently of revascularization ("All"
analysis) and in patients undergoing PCI ("PCI" analysis).
Methods: We included studies on NSTEACS from MEDLINE, EMBASE, CCT and
Biomedcentral. A random-effect model was applied. Pretreatment was deﬁned as the
administration of clopidogrel before PCI or catheterization. Primary efﬁcacy and
safety endpoints were all-cause mortality and major bleeding respectively, at longest
follow up available. Secondary endpoints included Major Adverse Cardiac Events
(MACE), Stroke, Stent Thrombosis, UVR.
Results: Of the 393 titles identiﬁed, 6 articles (3 RCTs and 3 observational studies)
met the inclusion criteria, published between August 2004 and January 2013,
including 28 350 patients, in those 14 678 from RCTs. 52% underwent PCI. Among
NSTEACS patients, clopidogrel pretreatment was not associated with a lower risk of
mortality ("all": OR¼0,85, 95%CI(0,66-1,08), p¼0,18 or "PCI": OR¼0,81, 95%
CI(0,58-1,13), p¼0,22). When considering all of studies (RCTs and registries)
together, the reduction in Ischemic endpoints (OR¼0,81, 95%CI(0,7-0,94), p¼0,006)
is counterbalanced by an increase in major bleeding (OR¼1,28, 95%CI(1,12-1,46),
p¼0,0002). The reduction in ischemic endpoints is no more signiﬁcant in the "PCI"
analysis (OR¼0,82, 95%CI(0,65-1,03), p¼0,10) while there is still an excess of major
bleeding in these patients (OR¼1,2, 95%CI(1-1,44), p¼0,048). ST, stroke and UVR
were not different between groups (pretreatment vs. no) in both analyses.
Conclusions: Clopidogrel pretreatment is not associated with a reduction of mortality
in NSTEACS patients; the reduction of MACE is counterbalanced by major bleeding
for "all" and "PCI" patients. The concept of systematic pretreatment in NSTE-ACS
patients needs reappraisal in the contemporary era.
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Background: Meta-analyses of PCI in NSTEMI/UA have shown GPIIbIIIa inhibitors
to be associated with a reduction in major adverse cardiac events at 30 days. However,
many of the trials were carried out before the routine use P2Y12 inhibitors which act
up-stream of GPIIbIIIa mediated platelet aggregation. Studies performed in the clo-
pidogrel yield conﬂicting results and registry data indicates that these agents are less
safe than trials would indicate.
Methods: We undertook an observational study at an interventional cardiology center
involving 5,227 patients undergoing PCI for NSTEMI/UA and receiving clopidogrel
and aspirin. GPIIbIIIa use was at the discretion of the operator. Primary outcome was
all cause mortality assessed at a median follow up of 4.6 years (IQR 3.0 - 6.2 years).
Results: 43.6% of patients were treated with GP IIb/IIIa inhibitors. The patients were
younger, more likely to be male, and have fewer comorbidities including previous MI,
CKD and PVD. They were less likely to suffer multivessel disease and more likely to
have a successful angiographic result. Kaplan-Meier analysis showed GP IIbIIIa
inhibitor use was associated with improved survival (p<0.001) and reduced MACE
(p¼0.011), but increased bleeding (p¼0.001). On multivariate analysis the beneﬁts
were lost for both survival (HR 0.876; 95% CI 0.693 – 1.108; p¼0.501) and MACE
(HR 1.036; 95% CI 0.883 – 1.216).ber 1, 2013 j TCT Abstracts/POSTER/Antiplatelets and Antithrombins
